Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia

被引:30
作者
Rocca, Paola [1 ]
Montemagni, Cristiana [1 ]
Castagna, Filomena [1 ]
Giugiario, Michela [1 ]
Scalese, Mara [2 ]
Bogetto, Filippo [1 ]
机构
[1] Univ Turin, Dept Neurosci, Unit Psychiat, I-10126 Turin, Italy
[2] Dept Mental Hlth Turin 1 S, I-10134 Turin, Italy
关键词
Executive functions; Negative symptoms; Path analysis; Schizophrenia; Second-generation antipsychotics; Social functioning; QUALITY-OF-LIFE; NEUROCOGNITIVE DEFICITS; COGNITIVE DEFICITS; CLINICAL PREDICTORS; TEST-PERFORMANCE; OLANZAPINE; HALOPERIDOL; 1ST-EPISODE; REMEDIATION; IMPAIRMENT;
D O I
10.1016/j.pnpbp.2009.01.002
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The purpose of this study was to examine the relative contributions of antipsychotic medication, negative symptoms and executive functions to impairment in social functioning in a sample of outpatients with stable schizophrenia. One-hundred and sixty-eight consecutive outpatients with stable schizophrenia were enrolled in a cross-sectional study. We performed a path analysis using multiple regression technique in order to assess the specific effect of antipsychotic type (first-generation antipsychotics versus second-generation antipsychotics) on social functioning and the possible mediating role of executive functions and negative symptoms. Our findings suggested that (i) second generation antipsychotics (SGAs) use predicted better social functioning (Beta=.24, p=.003) and better executive functions (Beta=.25, p=.003); conversely SGAs use was not associated with lesser negative symptoms (Beta=.00, p=.981); (ii) impaired executive functions and severity of negative symptoms were associated with worse social functioning (Beta=.19, p=.016; Beta=.28, p=.001): (iii) when we inserted in the model Positive and Negative Syndrome Scale - Negative Symptom subscale (PANSS-N) and Wisconsin Card Sorting Test - number of achieved sorting categories (WCST-cat), the former failed to show a mediation effect, while the latter seemed to mediate partially the effect of SGAs on social functioning. Taken together, the present results suggest that it is critical to examine individually executive functions and negative symptoms because they seem to relate to social functioning in different and independent ways and thus might represent separable treatment targets. Furthermore, social functioning appears a complex outcome multiply determined with no single predictor variable explaining a sufficient amount
引用
收藏
页码:373 / 379
页数:7
相关论文
共 97 条
[71]   Executive function in schizophrenia: Is it linked to psychosis and poor life functioning? [J].
Reed, RA ;
Harrow, M ;
Herbener, ES ;
Martin, EM .
JOURNAL OF NERVOUS AND MENTAL DISEASE, 2002, 190 (11) :725-732
[72]   Which executive skills should we target to affect social functioning and symptom change? A study of a cognitive remediation therapy program [J].
Reeder, C ;
Newton, E ;
Frangou, S ;
Wykes, T .
SCHIZOPHRENIA BULLETIN, 2004, 30 (01) :87-100
[73]   Cognitive predictors of social functioning improvements following cognitive remediation for schizophrenia [J].
Reeder, Clare ;
Smedley, Nicola ;
Butt, Kate ;
Bogner, Diana ;
Wykes, Til .
SCHIZOPHRENIA BULLETIN, 2006, 32 :S123-S131
[74]   Patient characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia [J].
Ren, XHS ;
Kazis, LE ;
Lee, AF ;
Huang, YH ;
Hamed, A ;
Cunningham, F ;
Herz, L ;
Miller, DR .
SCHIZOPHRENIA RESEARCH, 2005, 77 (2-3) :167-177
[75]   Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia [J].
Rosenheck, R ;
Dunn, L ;
Peszke, M ;
Cramer, J ;
Xu, WC ;
Thomas, J ;
Charney, D .
AMERICAN JOURNAL OF PSYCHIATRY, 1999, 156 (01) :88-93
[76]   Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia - A randomized controlled trial [J].
Rosenheck, R ;
Perlick, D ;
Bingham, S ;
Liu-Mares, W ;
Collins, J ;
Warren, S ;
Leslie, D ;
Allan, E ;
Campbell, EC ;
Caroff, S ;
Corwin, J ;
Davis, L ;
Douyon, R ;
Dunn, L ;
Evans, D ;
Frecska, E ;
Grabowski, J ;
Graeber, D ;
Herz, L ;
Kwon, K ;
Lawson, W ;
Mena, F ;
Sheikh, J ;
Smelson, D ;
Smith-Gamble, V .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (20) :2693-2702
[77]  
Rossa-Feres Denise de Cerqueira, 2006, Biota Neotrop., V6, P0, DOI 10.1590/S1676-06032006000100014
[78]   Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia [J].
Rothbard, AB ;
Kuno, E ;
Foley, K .
SCHIZOPHRENIA BULLETIN, 2003, 29 (03) :531-540
[79]   A review of longitudinal studies of cognitive functions in schizophrenia patients [J].
Rund, BR .
SCHIZOPHRENIA BULLETIN, 1998, 24 (03) :425-435
[80]   Social functioning and quality of life in the schizophrenic patient:: advantages of amisulpride [J].
Saleem, P ;
Olié, JP ;
Loo, H .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2002, 17 (01) :1-8